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Abstract
Background:  Pharmacogenetic testing to individualize ACE inhibitor therapy remains
controversial. We conducted a systematic review to assess the effect modification of the insertion/
deletion (I/D) polymorphism of the ACE gene on any outcome in patients treated with ACE
inhibitors for cardiovascular and/or renal disease.
Methods: Our systematic review involved searching six electronic databases, then contacting the
investigators (and pharmaceutical industry representatives) responsible for the creation of these
databases. Two reviewers independently selected relevant randomized, placebo-controlled trials
and abstracted from each study details on characteristics and quality.
Results: Eleven studies met our inclusion criteria. Despite repeated efforts to contact authors,
only four of the eleven studies provided sufficient data to quantify the effect modification by
genotypes. We observed a trend towards better response to ACE inhibitors in Caucasian DD
carriers compared to II carriers, in terms of blood pressure, proteinuria, glomerular filtration rate,
ACE activity and progression to end-stage renal failure. Pooling of the results was inappropriate,
due to heterogeneity in ethnicity, clinical domains and outcomes.
Conclusion: Lack of sufficient genetic data from the reviewed studies precluded drawing any
convincing conclusions. Better reporting of genetic data are needed to confirm our preliminary
observations concerning better response to ACE inhibitors among Caucasian DD carriers as
compared to II carriers.
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Background
Angiotensin-converting enzyme (ACE) inhibitors have
become a cornerstone in the management of patients with
cardiovascular disorders [1]. A large number of trials have
demonstrated important clinical benefits for this class of
drugs in patients with arterial hypertension [2], heart fail-
ure [3-6], diabetic and non-diabetic nephropathy [7-11]
and in patients who have undergone renal transplantation
[12,13]. Despite the generally positive effects of ACE
inhibitors, response to equivalent doses of these drugs
varies considerably among individuals [14]. As an exam-
ple, up to one third of patients with congestive heart fail-
ure may not tolerate or respond to ACE inhibitor therapy
[15,16].
In the late 1980s, researchers began investigating genetic
factors to determine the origins of inter-individual varia-
bility in patients' responses to ACE inhibitor therapy.
Rigat et al. [17] identified the insertion/deletion (I/D)
polymorphism of the ACE gene, which is based on the
presence (insertion) or absence (deletion) of a 287-bp ele-
ment on intron 16 on chromosome 17. They noted that
this polymorphism accounted for about 47% of the phe-
notypic variance for serum ACE levels. This led to the
hypothesis that the I/D polymorphism may influence the
effect of ACE inhibitors on clinical outcomes.
The ACE I/D polymorphism has received much attention
since its discovery, and many pharmacogenetic studies
have been conducted in different patient groups to assess
its effect modification. Debate, however, continues
regarding the extent and direction of its effect modifica-
tion [8,14,18]. The objective of our study was to systemat-
ically review all randomised, placebo-controlled trials
that had evaluated to what extent the ACE gene insertion/
deletion polymorphism influences treatment effects of
ACE inhibitors on any surrogate and on any clinically rel-
evant parameters in patients with cardiovascular diseases,
diabetes, renal transplantation and/or renal disease.
Methods
A previous publication details our study methodology
[19].
Search Strategy
We performed extensive literature searches in (Pre-)
MEDLINE (DataStar® version Cary North Carolina from
inception to 2005), EMBASE (DataStar®  version from
inception to 2005, Cary North Carolina), Biosis (Ovid®
version "Previews 1989 to 2005", New York), the
Cochrane Controlled Trials Register (CCTR <2rd Quarter
2005>, Oxford, United Kingdom) and the Science Cita-
tion Index. In collaboration with an information special-
ist, we carried out a preliminary literature search in
Medline to design the final search strategy [19]. We used
the following final search terms "peptidyl-dipeptidase A,"
"dipeptidyl-carboxypeptidase-inhibitor," "ACE inhibi-
tor," "genetics," "pharmacogenetic" and "polymorphism"
without language restriction. The last search was per-
formed in July, 2005.
We also contacted authors who had published pharmaco-
genetic analyses in the area of cardiovascular disease, dia-
betes, renal transplantation and/or renal diseases, as well
as relevant collaborative review groups of the Cochrane
Collaboration and pharmaceutical companies for addi-
tional published or unpublished data. Finally, we
reviewed bibliographies of all included studies to identify
additional relevant articles, using the "related articles"
function of PubMed and the citation index of ISI Web of
Science by entering all studies included in the review.
Inclusion criteria
Two reviewers (MS, MAP) independently assessed all
obtained titles and abstracts stored in Reference Manager®
files (Professional Edition Version 11, ISI ResearchSoft,
Berkeley, California) and ordered the full text of all poten-
tial articles. The two reviewers then examined the full texts
of all retrieved citations and included studies if they 1)
were randomised controlled trials comparing ACE inhibi-
tors to placebo or to a non-active treatment 2) included
patients with heart failure, primary and secondary hyper-
tension, coronary artery disease, diabetic nephropathy,
primary nephropathy and patients who had undergone
renal transplantation and 3) had determined the inser-
tion/deletion polymorphism.
Data extraction and quality assessment
Two reviewers independently abstracted the data and
assessed the quality of the included studies. We corrected
discordant items based on obvious reading errors and
resolved through consensus discordance based on real dif-
ferences in interpretation. A third reviewer (LMB) resolved
any remaining discrepancies.
We used a pre-designed and pilot-tested data extraction
form [19] and recorded details on study design, treat-
ments, patients, pharmacogenetic tests, outcome parame-
ters and results. We also focused our efforts on obtaining
additional unpublished data on genetic test information
and effect measures from authors of included studies. We
sent our requests and subsequent reminders for these data
to the first and last authors. To assess internal validity of
the included studies, we utilized a detailed list of quality
items [20], adding other items that we considered to be
important for pharmacogenetic studies (e.g., blinding of
laboratory assessor of study outcomes, blinding of out-
come assessor for genotypes and blinding of treatment
provider for genotypes).C
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Table 1: Internal validity of included randomized controlled trials [20]
Homogenous 
study group
Blinding of 
outcome 
assessor for 
genotype
Blinding of 
outcome 
assessor for 
treatment
Blinding of 
laboratory 
assessor for 
outcome
Blinding of 
treatmen t 
provider (doctor) 
for genotype
Blinding of 
treatment 
treatment
Blinding of 
patients for 
treatment
Check to what 
extent blinding 
was successful
Registration of 
loss to follow-up
Random 
allocation 
(description of 
procedure)
Treatment 
allocation 
concealed
Hernandez 2000 [25] +++- - -+-+- -
Hingorani 1997 [26] +-------- + / - -
Kventy 2000 [27] + / - ----+ +-+--
Meurice 2001 [28] + / - ----+ +-+- + / -
Okamura 1999 [21] --------+--
Okumura 2002 [29] +--+---- + / - --
Pedersen 1997 [30] -+++-++-+ + / --
Penno 1998 [23] + / -- -+ / -- ++ - +++
Perna 1999 [24] + / - ----+ +--+ +
Pinto1995 [31] -+ + +-+ +----
Van Geel 2003 [22] +-----+-- + / - -
Methods for 
dealing with 
missing values
Compliance 
checked
Analysis of CI Control for 
possible clinical 
and other 
confounders 
between 
genotypes
Control of co- 
interventions 
that bear on 
outcome for 
each genotype
Per protocol 
analysis
Intention to treat 
analysis
Hernandez 2000 [25] -+ / -- + - - +
Hingorani 1997 [26] +/- - - + - +/- -
Kventy 2000 [27] -------
Meurice 2001 [28] ++- -+++
Okamura1999 [21] --- + / - + / - --
Okumura 2002 [29] -----+-
Pedersen 1997 [30] -+ / - + / -- -+ / --
Penno 1998 [23] +/- +/- + +/- +/- +/- +
Perna 1999 [24] --- + / - --+
Pinto 1995 [31] -+--- + / - +
Van Geel 2003 [22] - - - +/- - +/- -
+ : Fulfilled; +/-: Partially fulfilled; -: Not fulfilled or no information providedCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:16 http://cvm.controlled-trials.com/content/6/1/16
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Methods of analysis and synthesis
Results of the data extraction and assessment of study
validity were summarized in structured tables. In compar-
ing the intervention group (ACE inhibitor) with control
groups (placebo or no active control), treatment effects
for each genetic subgroup (DD, DI and II) were assessed
by calculating mean differences for continuous outcomes
and relative risks for dichotomous outcomes. We also cal-
culated mean differences and relative risks between inter-
vention and control groups for the whole study
population, including all three genetic subgroups (DD/
DI/II), in order to provide an overall treatment effect of
the study. All statistical analyses were performed using the
Stata® statistical software package (StataCorp. 2004. Stata®
Statistical Software: Release 8.2 College Station, Texas,
USA).
Results
Figure 1 summarizes the selection process for the 656
identified abstracts. The eleven placebo-controlled, rand-
omized clinical trials (RCTs) that met the final inclusion
criteria involved post-myocardial infarction participants
Study flow from identification to final inclusion of studies Figure 1
Study flow from identification to final inclusion of studies. We identified 656 studies from which 11 studies eventually 
met the inclusion criteria.Current Controlled Trials in Cardiovascular Medicine 2005, 6:16 http://cvm.controlled-trials.com/content/6/1/16
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as well as subjects with congestive heart failure (n = 3),
arterial hypertension (n = 1), chronic proteinuric neph-
ropathies (n = 1), diabetes (n = 2) and patients who had
undergone coronary stent implantation or coronary angi-
oplasty (n = 3) or renal transplantation (n = 1). Only three
trials reported sufficient data [21-23] and the authors of
one trial sent additional requested data [24] for the anal-
ysis of effect modification. Despite repeated efforts to
obtain additional unpublished data from the remaining
trials, [23,25-31], we were unable to secure this
information.
Table 1 summarizes the methodological quality of all
included trials. Disagreement on quality assessment was
resolved through consensus. In general, the quality of tri-
als was poor to moderate. Trials scored poorly for blind-
ing, which was considered only for interventions but not
for genotypes. The four trials included in the analysis of
Table 2: Study characteristics of RCTs
Study Population ACE intervention 
Control intervention
Mean follow up Additional 
interventions
Outcomes
Perna 1999 [24] 212 (87 DD/ 99DI /26 II)
Caucasians, mean age of 50 years, with 
non- diabetic proteinuric chronic 
nephropathies: (urinary protein 
excretion> 1 g/24 h for last 3 months and 
creatinine clearance of 20 – 70 mL/min/
1.73m2)
Ramipril 1.25, increased 
to 2.5 or 5 mg/d Placebo 
or conventional treatment
30.3 months Conventional treatment 
for chronic nephropathy
Blood pressure, 
proteinuria, glomerular 
filtration rate, end stage 
renal disease
Van Geel 2003 [22] 86 (20 DD/ 43 DI/ 23 II)
Caucasians, mean age of 62 years, 
undergoing elective coronary artery 
bypass graft surgery; able to take the 
study drug for at least seven days before 
surgery
Quinapril 40 mg/d Placebo 12 months Aspirin, coumarin-
derivatives 
(anticoagulants), β- 
blocker, Ca+2 channel, 
nitrates
Plasma ACE activity
Okamura 1999 [21] 97 (16 DD/26 DI/36 II)
Asians, mean age of 63 years, with stable 
angina pectoris undergoing 
percutaneous transluminal 
coronary angioplasty
Imidapril 5 mg/d Placebo 3–6 months Aspirin and warfarin Minimal lumen 
diameter of coronary 
artery (net gain (mm), 
diameter stenosis %, late 
loss (mm) and loss 
index)
Penno 1998 [23] N = 530 (137 DD/296 DI /77 II)
Caucasians, mean age of 53, diabetes 
with normo- and microalbuminuria, 
diastolic blood pressure < 90 mmHg and 
> 75 mmHg, systolic blood pressure < 
155 mmHg
Lisinopril, 10–20mg/d 
Placebo
24 months Glycaemic control Proteinuria
Hernandez 2000 
[25]
N= 52 (25 DD/DI and 17 II)
Caucasians, mean age of 47, patients 
with renal transplantation, Stable 
renal function (creatinine clearance < 2.5 
mg/dL for more than 6 months), absence 
of renal artery stenosis or chronic 
allograft nephropathy, no renovascular 
hypertension, absence of proteinuria
Lisinopril, 10 mg/d 
Placebo
12 months Antithymocyte globulin, 
prednisone, cyclosporine, 
azathioprine
Serum creatinine, left 
ventricular ejection 
fraction, left ventricular 
isovolumetric relaxation 
time, left ventricular 
mass index
Hingorani 1997 [26] N = 125 (37 DD/70 DI/17 II)
Caucasians, mean age of 54, with 
untreated essential hypertension 
>160/90 (mainly primary care referrals
Captopril (50 mg/d), 
Enalapril (10 mg/d), 
Lisinopril (10 mg/d), 
Perindopril (4 mg/d) 
Placebo
4 weeks Ca+2-channel blocker Blood pressure
Kventy 2000 [27] N = 57 (17/DD/ 24 DI /16 II)
Caucasians, mean age of 45, with 
diabetes > 5 years, no microalbuminuria 
< 20 ug/min, albumin creatinine ratio < 
2.5 mg/mmol, normal serum creatinine 
and urine sediment
Perindopril, 4 mg/d 
Placebo
24 months None Albumin/creatinine 
ratio, blood pressure, 
glomerular filtration 
rate
Meurice 2001 [28] N = 91 (only DD)
Caucasians, mean age of 85, after 
coronary stent implantation
Quinapril 40 mg/d Placebo 6 months Aspirin (75–300 mg for 6 
months), ticlopidine 
(500mg for 1 months)
Minimal luminal 
diameter of coronary 
artery (restenosis)
Pedersen 1997 [30] N = 56 (14 DD, 26 DI,16 II)
Caucasians, mean age of 68, after 
acute myocardial infarction and 
moderate to severe left ventricular 
dysfunction (2–6 days after myocardial 
infarction)
Trandolapril, 4 mg/d 
Placebo
12 months None Tissue-type plasminogen 
activator [30]32 and 
plasminogen activator 
inhibitor (PAI) ACE 
activity
Pinto 1995 [31] N = 96 (34 DD/DI and 62 II)
Caucasians with first anterior 
myocardial infarction, treated with 
thrombolytic therapy (streptokinase 
intravenously)
Captopril 75 mg/d Placebo 12 months Streptokinase 
administration 
(1500000U)
Nitrates, Ca+2 channel 
blocker, β- blocker, 
aspirin, diuretics
End-systolic and end-
diastolic volume
Okumura 2002 [29] N = 100 (21 DD/22 DI/49 II)
Asians, mean age of 64, after coronary 
artery stent implantation
Quinapril 10–20 mg/d 
Placebo
6 months Ca+2 channel blocker, β- 
blocker, nitrates, aspirin, 
ticlopidine
Minimal lumen 
diameter of coronary 
artery (restenosis)Current Controlled Trials in Cardiovascular Medicine 2005, 6:16 http://cvm.controlled-trials.com/content/6/1/16
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the effect modification were of moderate methodological
quality. All four studies controlled for imbalances of base-
line characteristics between genotypes, whereas only three
studies [21,23,24] controlled for co-interventions that
might affect study outcomes.
Patient characteristics of included studies
Details about the individual trials and participant profiles
are provided in Table 2. Mean age of patients with cardio-
vascular disease and renal disease plus diabetes was 66
and 48 years, respectively. Nine of the 11 studies included
Caucasians, while two studies investigated Asian
populations.
Of the studies included in the analysis of the effect modi-
fication, three had enrolled Caucasians with non-diabetic
chronic nephropathies [24], insulin-dependent diabetes
mellitus [23] or patients undergoing elective coronary
artery bypass graft surgery [22]. One study included
Asians who had undergone percutanous transluminal cor-
onary angioplasty [21]. In all four studies, ACE inhibitors
were assigned as add-on therapy to slow disease
progression.
Comparisons between genotypes across clinical domains
The studies of Perna [24] and Van Geel [22], which were
based on previously published trials [32-34], provided
sufficient data to assess the overall ACE inhibitor effects
on different outcomes. Perna et al. assessed systolic and
diastolic blood pressure, proteinuria, glomerular filtration
rate and end-stage renal disease (defined as need for dial-
ysis), and Van Geel et al. assessed the plasma ACE activity
Comparison of treatment effects between genotypes in Caucasians Figure 2
Comparison of treatment effects between genotypes in Caucasians (results of the study of Van Geel [22] and Perna 
[24] on different outcomes). Treatment effects for each genotype (DD/DI/II) and overall treatment effects are presented as 
mean differences (from baseline to follow up) or relative risks with 95% confidence intervals.C
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Table 3: Data of effect modification for continuous clinical outcomes
Outcome Study Genotype N (ACE) Baseline Follow up Mean (SD) 
ACE inhibitor
N (Control) Baseline Follow up Mean (SD) 
Control group
Mean difference 
(estimated SD)
Overall effect (weighted 
mean and SD)
Reduction in ACE activity (U/I)
Van Geel [22] DD 8 31† 25† 6.29
(11.20)
12 27† 35† -7.82
(11.22)
14.11
(11.2)
9.84
(0.83)
DI 23 25.5† 22† 3.14
(10.31)
20 23† 20† -6.76
(10.28)
9.9
 (10.3)
II 11 18† 13† 4.61
(7.73)
12 18† 20† -1.42
(3.98))
6.03
 (6.1)
Reduction in end-systolic blood pressure (mmHg)
Perna [24] DD 42 147.8 
(19.1)
139.8 
(15.1)
8.8 
(14.58)
45 146 
(17.7)
142.8
(13.9)
3.2
(10.68)
5.6 
(12.8)
3.1
 (12.8)
DI 47 145.1
(18.9)
139
(17.5)
6.1
(13.88)
52 146.5
(17.2)
143.2 
(12.72)
3.3
(12.45)
2.8
 (13.08)
II 16 145.1
(18.4)
139.7 
(17.8)
5.4 
(11.29)
10 153.2
(15.9)
144
(14.7)
9.2 
(11.75)
-3.8
 (11.85)
Reduction in end-diastolic blood pressure (mmHg)
Perna [24] DD 42 89.9
(11)
86.2
(6.9)
3.8
(8.76)
45 88.6
(10.2)
87.4
(7.6)
1.2
(6.42)
2.6 
(7.8)
1.4
 (9.1)
DI 47 88.9
(13.9)
86.1
(9.64)
2.8
(12.10)
52 90.6
(12.6)
88.6
(8.86)
2.0
(9.7)
0.8
 (10.9)
II 16 90.8
(11.6)
85.3 
(5.8)
4.9
(7.61)
10 97.5
(6.1)
92.1
(6.25)
5.4
(5.67)
-0.5
 (7.0)
Reduction of proteinuria (g/24 h)
Perna [24] DD 42 2.85
(1.69)
2.28 
(1.5)
0.57
(1.18)
45 2.8
(1.7)
2.73
(1.4)
0.07
(1.10)
0.5
 (1.1)
0.33 
(1.2)
DI 47 3.3
(2.2)
2.97 
(1.97)
0.51 
(1.31)
52 3.8 
(2.5)
3.65 
(1.9)
0.15
(1.20)
0.36
 (1.2)
II 16 3.45 
(2.37)
3.41
(3.3)
0.05
(1.57)
10 3.4 
(1.7)
3.08
(0.32)
0.32
(1.15)
-0.37
 (1.4)
Decline of glomerular filtration rate (per months)
Perna [24] DD 42 44.2
(19.1)
n.a. -0.28 
(0.46)
45 40.2 
(17)
n.a. -0.43 
(0.63)
0.15
 (0.54)
0.08
 (0.63)
DI 47 45.3 
(20.7)
n.a. -0.48 
(0.83)
52 40.6
(17.1)
n.a. -0.52
(0.68)
0.04 
(0.75)
II 16 47.3 
(23.5)
n.a. -0.38 
(0.41)
10 47.8
(20.5)
n.a. -0.37
(0.53)
-0.01
 (0.43)
Albumin excretion rate(µg/min)
Penno [23] DD 71 8.1* 17.1† 9.00† 66 8.1* 17.2† 9.78† -0.78 -7.33
DI 154 7.6* 17.4† 9.80† 142 7.6* 19.1† 11.5† -1.70
II 29 9.2* 16.2† 7.00† 48 9.2* 24.3† 15.11† -8.11
Net gain (mm)
Okamura [21] DD 9 0.64
(0.27)
1.09
(0.66))
0.45 
(0.23)
70 . 4 9
(0.27)
1.64
(0.96)
1.16 
(0.26)
-0.71
 (0.2)
0.03 
(0.28)
DI 13 0.58 
(0.32)
1.62 
(0.79)
1.04 
(0.24)
13 0.53 
(0.18)
1.42 
(0.97)
0.89 
(0.26)
0.15
 (0.3)
II 10 0.55 
(0.25)
1.82 
(0.69)
1.27 
(0.21)
26 0.65 
(0.16)
1.42 
(0.54)
0.77 
(0.18)
0.5
 (0.2)
Late Loss (mm)
Okamura [21] DD 9 2.43
(0.54)
1.09
(0.66))
1.34 
(0.23)
7 2.46 
(0.57)
1.64 
(0.96)
0.82
(0.24)
-0.52
 (0.67)
0.15
 (0.74)
DI 13 2.58 
(0.55)
1.62 
(0.79)
0.96 
(0.21)
13 2.32 
(0.49)
1.42 
(0.97)
0.90 
(0.23)
-0.06
 (0.79)
I24I1 0 2 . 4 4
(0.51)
1.82
(0.69)
0.62
(0.16)
26 2.65
(0.25)
1.42 
(0.54)
1.23 
(0.16)
0.61
 (0.75)C
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Loss index (% at follow up)
Okamura [21] DD 9 n.a. n.a. 0.78
(0.13)
7 n.a. n.a. 0.42
(0.12)
-0.36
 (0.36)
0.03
 (0.39)
DI 13 n.a. n.a. 0.53
(0.12)
13 n.a. n.a. 0.49
(0.13)
-0.04
 (0.45)
II 10 n.a. n.a. 0.38
(0.09)
26 n.a. n.a. 0.63
(0.08)
0.25
 (0.37)
Diameter stenosis
Okamura [21] DD 9 n.a. n.a. 57.4
(23.4)
7 n.a. n.a. 40.08
(26.4)
-0.17
 (0.25)
0.03
 (0.39)
DI 13 n.a. n.a. 43.8 
(25.2)
13 n.a. n.a. 45.1 
(33.9)
0.01 
(0.30)
II 10 n.a. n.a. 34.3
(19.9)
26 n.a. n.a. 48.2
(30.6)
0.14
 (0.28)
Values are presented as means and SD; n.a.: not available; * indicates combined baseline data for intervention and control group; † indicates extracted values of figures (no SD)
Table 3: Data of effect modification for continuous clinical outcomes (Continued)Current Controlled Trials in Cardiovascular Medicine 2005, 6:16 http://cvm.controlled-trials.com/content/6/1/16
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for each genotype. In these two studies, which included
Caucasians with the DD genotype, ACE inhibitors
reduced systolic blood pressure more effectively (mean
difference 5.6 mmHg, 95% confidence intervals [0.96 to
10.97]) compared to the overall treatment effect (3.1
mmHg [-2.60 to 8.88]), while in II carriers, ACE inhibitors
increased systolic blood pressure (-3.8 mmHg [-12.92 to
5.32]) compared to placebo (Figure 2). Effect modifica-
tion with benefit for DD carriers and treatment failure for
II carriers was also present for diastolic blood pressure,
decline of glomerular filtration rate, ACE activity and pro-
gression to end-stage renal disease. Differences between
genotypes failed to achieve statistical significance. Details
on baseline characteristics and differences in treatment
effects across genotypes are shown in Table 3. The risk
reduction of the incidence of end-stage renal disease was
22% (4% to 39%) for DD carriers compared to 2% (-14%
to 18%) for DI carriers and 1% (-21% to 41%) for II car-
riers (see Figure 2).
The study of Penno et al. [23] was also based on a previ-
ously published trial [11]. Caucasian patients with insu-
lin-dependent diabetes mellitus and normoalbuminuria
(83% in DD, 87% in DI and 81% in II) at baseline showed
comparable treatment effects from ACE inhibitors
between genotypes within the first 12 months. Thereafter,
II carriers had an enhanced response to ACE inhibitors
with regard to reduction of albumin excretion rate (8.1
µg/min) compared to DI (1.7µg/min) and DD carriers
(0.8µg/min). Patients with II genotypes also exhibited the
largest benefit in terms of progression from normoalbu-
minuria to micro- or macroalbuminuria (Risk ratio 0.36
[0.05 to 2.74]), whereas in DD carriers, ACE inhibitors
tended to have a negative effect (risk ratio of 1.18 [0.33 to
4.20]). There were, however, baseline imbalances in
important prognostic variables between genotypes.
Compared to DI and DD carriers, II carriers had pro-
nounced albuminuria at baseline, with placebo group
participants experiencing the greatest progression of albu-
min excretion rate.
In the study of Okamura [21], which included a Japanese
population, only the II subgroup had an enhanced
response to ACE inhibitors (manifested by prevention of
restenosis, as defined by most indexes after percutaneous
transluminal coronary angioplasty). Otherwise, the over-
all treatment effects were not significant (Figure 3). II car-
riers showed 1) an increased net gain in minimal lumen
diameter of 0.5 mm (-1.04 to 1.04) compared to the over-
all effect of 0.14 mm (-0.49 to 0.76), 2) a higher percent-
age of change in diameter stenosis 0.14 (-0.06 to 0.33)
compared to the overall effect of 0.03 (-0.16 to 0.22), 3)
an improved late loss of lumen diameter of 0.61 mm
(0.13 to 1.09) compared to the overall effect of 0.15 mm
(-0.33 to 0.64) and 4) a better loss index (the ratio of late
loss to acute gain) of 0.25 (-0.02 to 0.52) compared to the
overall effect of 0.03 (-0.24 to 0.29). In the DD subgroup,
ACE inhibitors showed a negative effect on changes in
minimal lumen diameter of coronary arteries. Thus,
Japanese DD carriers did not benefit from ACE inhibitor
therapy, while DI carriers demonstrated moderate
responses and II carriers showed the greatest treatment
response.
Discussion
Based on our systematic review, evidence quantifying the
extent of effect modification related to the I/D polymor-
phism is sparse. We did note a trend towards better
response to ACE inhibitor therapy in DD Caucasians as
compared to II carriers, who seemed not to benefit.
The strengths of this review include the comprehensive lit-
erature search and strict adherence to systematic review
methodology. We restricted our analyses to trials with pla-
cebo controls, as studies without a placebo control group
do not allow for estimation of the ACE inhibitor effect
and are likely to be confounded [35,36].
Although we identified 11 randomised controlled trials
that assessed differences in treatment effects among geno-
types, only the results of four trials studying 925 patients
contributed to our analyses. The authors of the remaining
seven studies that included 577 patients did not provide
data about genetic subgroups in the intervention and con-
trol arms [26-28,30]. Others presented combined results
for two different genotypes [25,29,31]. We made substan-
tial efforts to contact the authors of these seven trials as
well as researchers known to be active in the field of phar-
macogenetics, but we did not succeed in receiving addi-
tional unpublished data. Thus, our analysis might be
subject to publication bias. While publication bias is a
common problem in systematic reviews, the situation
might be aggravated in reviews of genetic data. Reporting
of genetic data is in general poor and most "negative"
results of association studies do not even reach conference
proceedings [37].
Despite an overall lack of evidence, some of our findings
merit attention. For example, the second largest study of
Caucasians with chronic nephropathies [24] showed a
consistent trend towards a beneficial effect for various sur-
rogate and clinical outcomes, whereas II carriers appeared
to be unresponsive to treatment. Comparable results have
been observed in the reduction of plasma ACE activity for
patients after coronary artery bypass surgery [22]. On the
other hand, the findings of the largest study [23], includ-
ing diabetic patients with normo- or microalbuminuria,
yielded conflicting results to the above-discussed effect
modification in Caucasians. In terms of baseline values of
the main outcome (level of albumin extraction rates), dif-Current Controlled Trials in Cardiovascular Medicine 2005, 6:16 http://cvm.controlled-trials.com/content/6/1/16
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ferences between genotypes limit the interpretation of
these results. Looking at the results of the Asian study
[21], DD carriers did not benefit from ACE inhibitor ther-
apy while DI carriers showed moderate and II carriers
showed large treatment responses. Arguably, these con-
flicting results for treatment success of ACE inhibitors
between the genetic subgroups in Asians and Caucasians
might be attributed to a different genotype-phenotype
relationship. In Asians, the prevalence of the D allele fre-
quency ranges from 27 to 40 percent, whereas in Cauca-
sians, it ranges from 50 to 63 percent. Additional ethnic
factors might also affect these genotype-phenotype rela-
tionships. For example, the level of circulating ACE is 60%
higher in Caucasian DD carriers than in II carriers,
whereas for Asians, there are no differences [8,38]
From the patient and clinician's perspective, it is still too
early to draw solid conclusions about the optimal treat-
ment among different genotypes. We can, however, spec-
ulate that an effect modification exists and that
pharmacogenetic testing of the I/D polymorphism might
provide additional information about the adequate
treatment for these patients. From the public health per-
spective, it remains unclear whether pharmacogenetic
testing would be justifiable in clinical practice. Before
investing additional resources to reevaluate our prelimi-
nary observations in a primary study of high methodolog-
ical quality, it might be informative to assess whether
screening patients for the I/D polymorphism would have
potential economic value. One recent economic analysis
showed, for example, that screening men for the I/D pol-
ymorphism before starting lipid-lowering therapy with
Comparison of treatment effects between genotypes in Asians Figure 3
Comparison of treatment effects between genotypes in Asians (results of the study of Okamura [21] on differences in 
minimal luminal diameter). Effects for each genotype (DD/DI/II) and the overall treatment effect are presented as mean differ-
ences (from follow-up to baseline) with 95% confidence intervals.Current Controlled Trials in Cardiovascular Medicine 2005, 6:16 http://cvm.controlled-trials.com/content/6/1/16
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statins would result in considerable cost savings [39].
Thus, estimations of the potential cost-effectiveness of
this pharmacogenetic test might be worth considering
before starting ACE inhibitor treatment.
Conclusion
We conclude that evidence is still scarce as there are few
pharmacogenetic studies of high methodological quality
with comprehensive reporting of their results. Neverthe-
less we did note a trend towards better response to ACE
inhibitors in Caucasian DD carriers compared to II carri-
ers. Future efforts should focus on conducting high-qual-
ity pharmacogenetic studies, and reporting of genetic data
should be improved.
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